In this episode of the Drug Solutions Podcast, Feliza Mirasol, Pharmaceutical Technology’s science editor, discusses technologies enabling biologics and emerging therapies manufacturing and development with Barry Holtz, PhD, chief scientific officer of Phylloceuticals, and Professor Yaakov Nahmias, founder and chief scientific officer, Tissue Dynamics and founder and president, Future Meat Technologies.
Partnering with an experienced service provider can help companies unlock the commercial potential of new therapeutic approaches.
In this episode of the Drug Solutions Podcast, Meg Rivers, senior editor, interviews Joy Aho, senior product manager at Be The Match BioTherapies, about sourcing autologous and allogeneic cell therapies.
Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.
A key benefit for companies when outsourcing formulation development is the broad experience they can gain from a dedicated service provider, particularly for niche markets.
Industry experts share their top outsourcing tips from both the perspective of companies offering outsourcing services as well as for companies looking to outsource.
Shifting demands from industry innovators is leading to an increased need for flexible and agile outsourcing partners offering broad and integrated models.
CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.
CDMOs offer expertise and customization options for sponsors of orphan drugs.
In this episode of the Drug Solutions podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview experts on up-and-coming 2022 trends in the bio/pharma industry.
Sterling Pharma Solutions has announced a £10 million (US$13.5 million) investment into process development and manufacturing capacity at its site in Dudley, UK.
Investing in formulation strategies earlier on in development will maximize the chance of success.
Dosage form priorities are shifting to focus on user-friendliness, leading to greater engagement with outsourcing partners earlier in development timelines.
Collaborative partnerships can foster success in formulation development projects.
The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.
The CRO market will see greater consolidation by both financial buyers looking to consolidate smaller players and larger CRO players wanting to expand into value-added specialty service areas.
The companies will utilize the Cocoon Platform for clinical point-of-care manufacturing.
The companies have entered into an agreement to develop processes for a novel immunotherapy protein.
Vectura has signed an agreement with Incannex Healthcare for the pre-clinical development of IHL-216A, an inhaled drug product for the treatment of traumatic brain injury.
Thought and foresight into method development stages can ensure costly errors and delays are avoided later on.
Outsourcing method development offers multiple benefits to companies, including access to experience and expertise, streamlined costs, and development time efficiencies.
An integrated CMC provider can help smaller companies to streamline development timelines and reduce project management complexity when compared with multi-provider models.
The rapid and efficient delivery of innovative treatments through the COVID-19 pandemic has demonstrated the value of collaborations within the bio/pharma industry.
Outsourcing partners can provide a multitude of advantages in the development of drug delivery solutions, including those designed for targeted patient populations.
The right partner can help companies overcome key formulation challenges for biologic drugs.
